Calcium metabolism

Product name

Intact Fibroblast Growth Factor 23

iFGF23

Cat-Nr.BI-20700
Range0 – 1600 pg/ml
Sensitivity12.5 pg/ml (STD2 50 pg/ml)
Incubation time3 h / 30 min
Sample volume50 μl
Sample type

EDTA/Heparin/Citrate plasma, serum

Sample preparation

Centrifuge freshly collected blood as soon as possible
Store centrifuged samples at -20°C for longer storage.
Samples are stable up to 4 freeze and thaw cycles.
Hemolyzed or lipemic samples may cause erroneous results.

Reference values

Median EDTA plasma (n=22): 24.4 pg/ml
Median Heparin plasma (n=22): 26.14 pg/ml
Median Citrate plasma (n=22): 17.4 pg/ml
Median serum (n=22): 14.8 pg/ml

Species

Human

Tests96
MethodELISA
Intended use

Intended use:

FGF23 (fibroblast growth factor 23) is a member of the fibroblast growth factor family and controls phosphate and vitamin D homeostasis. The full-length protein comprises 251 amino acids including a 24 amino acid signal peptide. The N-terminal FGF region of FGF23 is separated from the C-terminal region by a proteolytic cleavage site. A fraction of FGF23 is proteolytically processed between arginine179 and serine180 to generate N-terminal and Cterminal fragments. Therefore, the main forms of FGF23 present in human circulation are hormonally intact FGF23 and inactive N-terminal and C-terminal fragments. FGF23 binds to FGF receptor 1c (FGFR1c) with its N-terminal region, while the C-terminal region interacts with the co-receptor α-Klotho to confer high-affinity binding to the receptor. FGFR1c and α-Klotho are expressed in the distal nephron and the parathyroid gland. Co-receptor independent signaling of FGF23 has been described for other FGFRs, which are expressed in a variety of tissues. The main source of FGF23 are osteocytes in the bone.

Intended applications:

  • Bone diseases
  • Cancer
  • Cardiovascular diseases
  • Endocrine disorders
  • Metabolic disorders
  • Kidney diseases
Product informations

Back to overview